艾克美制药

Alkermes PLC is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 20% premium over our quantitative fair value estimate of $35.75 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 25.9%, which lies in the bottom 30% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's lack of growth is an additional cause for concern. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's EPS 5-year growth of -25.7%, for example, falls in the bottom 10% compared with peers globally. On a relative basis, EPS growth has lagged over the last five years, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.